Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board
Chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) is one of the most important medical and social problems associated with significant risks for patients and a burden on the national healthcare system. There are significant unmet diagnostic and therapeutic needs of CKD in T2D patie...
Main Authors: | M. V. Shestakova, V. A. Dobronravov, A. S. Ametov, M. B. Antsiferov, M. M. Batyushin, I. N. Bobkova, G. R. Galstyan, T. Y. Demidova, V. V. Klimontov, A. M. Mkrtumyan, N. A. Petunina, E. I. Prokopenko, N. V. Chebotareva, M. S. Shamkhalova |
---|---|
Format: | Article |
Language: | English |
Published: |
Endocrinology Research Centre
2023-11-01
|
Series: | Сахарный диабет |
Subjects: | |
Online Access: | https://www.dia-endojournals.ru/jour/article/view/13020 |
Similar Items
-
Administration of finerenone in chronic kidney disease
by: Mohsen Akhavan Sepahi, et al.
Published: (2023-01-01) -
FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes
by: M. S. Shamkhalova, et al.
Published: (2023-12-01) -
Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease
by: Monarch Shah, et al.
Published: (2023-09-01) -
Finerenone, a Non-Steroidal Mineralocorticoid Receptor Antagonist, Reduces Vascular Injury and Increases Regulatory T-Cells: Studies in Rodents with Diabetic and Neovascular Retinopathy
by: Jack R. Jerome, et al.
Published: (2023-01-01) -
Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies
by: Franz Schaefer, et al.
Published: (2024-03-01)